Stock Trading Canary

Data as of 5 Nov 2026 · 中文

← United States · Coverage record

US · SEC FORM 4

Aspen Neuroscience, Inc.

ASPE · — · CIK 0002124080 · Healthcare · Biotechnology

INSIDER SIGNAL

86.0 / 100

4 buyers · 6 purchase transaction lines · $68.0M gross purchase

WHY THIS SIGNAL?

Buyer breadthStrong
Purchase sizeStrong
RoleModerate
RecencyStrong
ConvictionStrong
Score anatomy

Each bar is that part's points in the score; the five parts add up to the score.

Number of buyers+28.0 / 35
Amount bought+24.5 / 25
Buyers' roles+14.0 / 20
How recent+9.5 / 10
Buying against selling+10.0 / 10

What is holding the score back?

  • ⚠ Buyers' roles add little · most senior buyer: TenPercentOwner (CEO, chair and 10% owners score lowest)
  • ✓ Many buyers · 4 or more insiders
  • ✓ Recent buying · latest purchase 2026-11-02

Average daily trading volume is shown elsewhere on the page as market context; it is not part of the score.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes use transaction dates. Diamonds show later public disclosure dates; the transaction was not public before then. Sales remain context only.

MayJunJulAugSepOctNov
ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERTTenPercentOwner
○●
ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLCDirector,TenPercentOwner
○◇●◇
Thompson Peter A.Director,TenPercentOwner
○◇●◇
ARCH Venture Fund XIV, L.P.; ARCH Venture Partners XIV, L.P.; ARCH Venture Partners XIV, LLC; BERNS PAUL LTenPercentOwner
●
Hasnain FaheemExecutive Chair
○
Spaventa AndrewDirector
○
● Purchase▼ Sale○ Other◇ Public disclosure

—

Purchase breadth & concentration

QUALIFYING BUYERS4
PURCHASE CONCENTRATION29%Largest buyer: ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERT · $20.0M
CLUSTER BUYING · 15D4 insidersPeak activity: 2026-11-02–2026-11-02

Roles in the peak window: Director,TenPercentOwner, TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

86.0 / 100

Latest recorded score

↑ +14.1 ptsversus the previous recorded snapshot
  1. 71.9
  2. 86.0

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

6Purchases
0Sales
21Other Form 4 lines
6SEC filings · 365 days
BUYING6 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER21 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot detected in parsed evidence

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
—
3M
—
6M
—
12M
—

Volatility & liquidity

Volatility
—
Beta
—
Avg daily value
USD 10.9M

Valuation

Market cap
USD 371.0M
P/E
—

Fundamentals

Profit margin
0.0%
ROE
—
Industry
Biotechnology

Market data

Price data up to: 2026-11-05 · Price source: OpenBB/yfinance · From Yahoo Finance: Market cap, Profit margin · Status: PASS

Short interest

The FINRA report lists no short interest for this ticker.

FINRA settlement date: 2026-10-15 · Captured 2026-11-03 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateDisclosure dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-11-022026-11-04Thompson Peter A.Purchase (P)Common Stock1,000,000USD 15.00USD 15,000,000SEC filing ↗
2026-11-022026-11-04ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLCPurchase (P)Common Stock1,000,000USD 15.00USD 15,000,000SEC filing ↗
2026-11-022026-11-02ARCH Venture Fund XIV, L.P.; ARCH Venture Partners XIV, L.P.; ARCH Venture Partners XIV, LLC; BERNS PAUL LPurchase (P)Common Stock1,200,000USD 15.00USD 18,000,000SEC filing ↗
2026-11-022026-11-02ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERTPurchase (P)Common Stock1,333,333USD 15.00USD 19,999,995SEC filing ↗

Form 4 evidence

27 transaction lines in the latest 365-day window; 27 in local history.

Trade dateDisclosure dateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-11-022026-11-04Thompson Peter A.Purchase (P)Common Stock1,000,000USD 15.00USD 15,000,000SEC filing ↗
2026-11-022026-11-04Thompson Peter A.C (C)Common Stock2,589,132USD —USD —SEC filing ↗
2026-11-022026-11-04ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLCPurchase (P)Common Stock1,000,000USD 15.00USD 15,000,000SEC filing ↗
Show recent Form 4 evidence (9 grouped rows)
Trade dateDisclosure dateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-11-022026-11-04Thompson Peter A.Purchase (P)Common Stock1,000,000USD 15.00USD 15,000,000SEC filing ↗
2026-11-022026-11-04Thompson Peter A.C (C)Common Stock2,589,132USD —USD —SEC filing ↗
2026-11-022026-11-04ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLCPurchase (P)Common Stock1,000,000USD 15.00USD 15,000,000SEC filing ↗
2026-11-022026-11-04ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLCC (C)Common Stock2,589,132USD —USD —SEC filing ↗
2026-11-022026-11-02Spaventa AndrewC (C)Common Stock250,415USD —USD —SEC filing ↗
2026-11-022026-11-02Hasnain FaheemC (C)Common Stock36,349USD —USD —SEC filing ↗
2026-11-022026-11-02ARCH Venture Fund XIV, L.P.; ARCH Venture Partners XIV, L.P.; ARCH Venture Partners XIV, LLC; BERNS PAUL LPurchase (P)Common Stock1,200,000USD 15.00USD 18,000,000SEC filing ↗
2026-11-022026-11-02ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERTPurchase (P)Common Stock1,333,333USD 15.00USD 19,999,995SEC filing ↗
2026-11-022026-11-02ARCH Venture Fund X Overage, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERTC (C)Common Stock1,541,537USD —USD —SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-11-05
Ranking versionUS-v1.2
Data qualityREVIEW MAPPING_REVIEW · mapping-review-required
TickerASPE
CIK0002124080
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
Exchange—

Data coverage

Local Form 4 history27 transaction lines from 2026-11-02 to 2026-11-02
6 P purchase lines · 0 S sale lines · 21 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-11-05. Mapping status is an audit field and does not erase SEC filing evidence.